2Aronson NK,Cull A,Keasa S,et el.The European Organization for Research and Treatment of Cancer(EORTC)modular approach to quality of life assessment in oncolog[J].Int J Ment He -alth,1994,23(2):75-961.
3Aaronson NK,Ahmedzai S,Bergman B,et al.The European Organization for Research and Treatment of Cancer QLQ-C30:a quality-of-life instrument for use in international clinical tfi- als in oncology [J]. J NatI Cancer Inst,1993,85(5):365-376.
4Chang CH,Lin JW,Wu LC,et al.Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus [J].J Clin Endocrinol Match,2012.97(7):E 1170-E 1175.
5Zhang Z J, Bi Y, Li S, et al. Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis [J]. Am J Epidemiol,2014,180(1):1 1-14.
6Ding J,Tang J,Chen X,et al.Expression characteristics of proteins of the insulin-like growth factor axis in non-small cell lung cancer patients with preexisting type 2 diabetes mellitus [J].Asian Pac J Cancer Prev,2013,14(lO):5675-5680.
7Hemminki K, liX, Sundquist j, et al. Risk of cancer forlowing hospi- tation for type 2 diabetes[J]. Oneologist, 2010, 15(6): 548-555.
